ALTEOGEN Inc. 196170
KRX · South Korea · Health Technology
KRW 265,000.00+10,500.00 (+4.13%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer
Novartis (SWX:NOVN) is back in focus after reporting positive Phase III REMODEL-1 and REMODEL-2 results for its oral BTK inhibitor remibrutinib in relapsing multiple sclerosis, supporting planned global regulatory filings. At a share price of CHF131.32, Novartis has seen building momentum, with a 7 day share price return of 5.36% and a 90 day share price return of 11.31%. Total shareholder return sits at 30.21% over one year and 108.91% over five years, helped recently by the remibrutinib...
The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.